Who will support independent patient groups?BMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g6306 (Published 21 October 2014) Cite this as: BMJ 2014;349:g6306
- Sharon Batt, PhD adjunct1
- 1Department of Bioethics, Faculty of Medicine, Dalhousie University, NS, Canada B3H 4R2
Arie and Mahony imply that transparency would somehow neutralise the bias that funding from drug companies may introduce into patient advocacy groups’ judgments on drugs.1 Research into the financial ties between drug companies and physicians, medical researchers, and others shows that transparency alone does not ensure that patients’ interests take precedence over those of the industry. …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial